| 1 |
Khoury M, Cuenca J, Cruz F F, et al. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19[J]. Eur Respir J, 2020, 55(6):2000858.
|
| 2 |
新型冠状病毒肺炎疫情实时动态追踪[EB/OL].(2020-05-01)
URL
|
| 3 |
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and tmprss2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020,181(2):271-280.e8.
|
| 4 |
Hamming I, Timens W, Bulthuis M, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis[J]. J Pathol, 2004, 203(2):631-637.
|
| 5 |
Iwata-Yoshikawa N, Okamura T, Shimizu Y, et al. TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection[J]. J Virol, 2019, 93(6): e01815-18.
|
| 6 |
Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2[J]. Cell, 2020, 181(4):894-904.e9.
|
| 7 |
Chu H, Chan JF, Wang Y. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19[J]. Clin Infect Dis, 2020, ciaa410.
|
| 8 |
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506.
|
| 9 |
Ouyang Y, Yin J, Wang W, et al. Down-regulated gene expression spectrum and immune responses changed during the disease progression in COVID-19 patients[J]. Clin Infect Dis, 2020, ciaa462.
|
| 10 |
Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab[J]. Proc Natl Acad Sci U S A, 2020, 117(20):10970-10975.
|
| 11 |
Zhou Y, Fu B, Zheng X, et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients[J]. National Science Review, 2020, 7(6):998-1002.
|
| 12 |
Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin-converting enzyme-2 (ACE2), SARS-CoV-2 and pathophysiology of coronavirus disease 2019 (COVID-19)[J]. J Pathol, 2020, 251(3):228-248.
|
| 13 |
Jin Y, Yang H, Ji W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19[J]. Viruses, 2020, 12(4):372.
|
| 14 |
Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice[J]. Exp Physiol, 2008, 93(5):543-548.
|
| 15 |
Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID- 19[J]. Thromb Res, 2020, 191:145-147.
|
| 16 |
Fox SE, Akmatbekov A, Harbert JL, et al. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans[J]. Lancet Respir Med, 2020, 8(7):681-686.
|
| 17 |
Wang L, Li Y, Chen X, et al. MCP-1, MIP-1, IL-8 and ischemic cerebral tissue enhance human bone marrow stromal cell migration in interface culture[J]. Hematology, 2002, 7(2):113-117.
|
| 18 |
Wang L, Li Y, Chen J, et al. Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture[J]. Exp Hematol, 2002, 30(7):831-836.
|
| 19 |
Ji JF, He BP, Dheen ST, et al. Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury[J]. Stem Cells, 2004, 22(3):415-427.
|
| 20 |
Leibacher J, Henschler R. Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells[J]. Stem Cell Res Ther, 2016, 7:7.
|
| 21 |
Rustad KC, Gurtner GC. Mesenchymal stem cells home to sites of injury and inflammation[J]. Adv Wound Care (New Rochelle), 2012,1(4):147-152.
|
| 22 |
Rippon HJ, Polak JM, Qin M, et al. Derivation of distal lung epithelial progenitors from murine embryonic stem cells using a novel three-step differentiation protocol[J]. Stem Cells, 2006, 24(5):1389-1398.
|
| 23 |
Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects[J]. Proc Natl Acad Sci U S A, 2003, 100(14):8407-8411.
|
| 24 |
Volarevic V, Nurkovic J, Arsenijevic N, et al. Concise review: Therapeutic potential of mesenchymal stem cells for the treatment of acute liver failure and cirrhosis[J]. Stem Cells, 2014, 32(11):2818-2823.
|
| 25 |
Lee RH, Seo MJ, Reger RL, et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice[J]. Proc Natl Acad Sci U S A, 2006, 103(46):17438-17443.
|
| 26 |
Humphreys B, Bonventre J. Mesenchymal stem cells in acute kidney injury[J]. Annu Rev Med, 2008, 59:311-325.
|
| 27 |
Morigi M, Rota C, Remuzzi G. Mesenchymal stem cells in kidney repair[J]. Methods Mol Biol, 2016, 1416:89-107.
|
| 28 |
Rubio GA, Elliot SJ, Wikramanayake TC, et al. Mesenchymal stromal cells prevent bleomycin-induced lung and skin fibrosis in aged mice and restore wound healing[J]. J Cell Physiol, 2018, 233(8):5503-5512.
|
| 29 |
Guan X, Song L, Han F, et al. Mesenchymal stem cells protect cigarette smoke-damaged lung and pulmonary function partly via VEGF-VEGF receptors[J]. J Cell Biochem, 2013, 114(2):323-335.
|
| 30 |
Kennelly H, Mahon BP, English K. Human mesenchymal stromal cells exert HGF dependent cytoprotective effects in a human relevant pre-clinical model of COPD[J]. Sci Rep, 2016, 6(1):38207.
|
| 31 |
Bernard O, Jeny F, Uzunhan Y, et al. Mesenchymal stem cells reduce hypoxia-induced apoptosis in alveolar epithelial cells by modulating HIF and ROS hypoxic signaling[J]. Am J Physiol Lung Cell Mol Physiol, 2018, 314(3):L360-L371.
|
| 32 |
Behnke J, Kremer S, Shahzad T, et al. MSC Based Therapies-New Perspectives for the injured lung[J]. J Clin Med, 2020, 9(3):682.
|
| 33 |
Naji A, Eitoku M, Favier B, et al. Biological functions of mesenchymal stem cells and clinical implications[J]. Cell Mol Life Sci, 2019, 76(17): 3323-3348.
|
| 34 |
Gao F, Chiu SM, Motan DAL, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects[J]. Cell Death Dis, 2016, 7(1):e2062.
|
| 35 |
Goodwin M, Sueblinvong V, Eisenhauer P, et al. Bone marrow-derived mesenchymal stromal cells inhibit Th2-Mediated allergic airways inflammation in mice[J]. Stem Cells, 2011, 29(7):1137-1148.
|
| 36 |
Park K, Svennerholm K, Shelke GV, et al. Mesenchymal stromal cell-derived nanovesicles ameliorate bacterial outer membrane vesicle-induced sepsis via IL-10[J]. Stem Cell Res Ther, 2019,10(1):231.
|
| 37 |
Li Y, Xu J, Shi W, et al. Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice[J]. Stem Cell Res Ther, 2016,7(1):159.
|
| 38 |
Zhu Y, Feng X, Abbott J, et al. Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice[J]. Stem Cells, 2014, 32(1):116-125.
|
| 39 |
Li JW, Wei L, Han Z, et al. Mesenchymal stromal cells-derived exosomes alleviate ischemia/reperfusion injury in mouse lung by transporting anti-apoptotic miR-21-5p[J]. Eur J Pharmacol, 2019, 852: 68-76.
|
| 40 |
Bari E, Ferrarotti I, Di Silvestre D, et al. Adipose mesenchymal extracellular vesicles as Alpha-1-Antitrypsin physiological delivery systems for lung regeneration[J]. Cells, 2019, 8(9):965.
|
| 41 |
Harrell CR, Jovicic N, Djonov V, et al. Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases[J]. Cells, 2019, 8(12):1605.
|
| 42 |
Liu A, Zhang X, He H, et al. Therapeutic potential of mesenchymal stem/stromal cell-derived secretome and vesicles for lung injury and disease[J]. Expert Opin Biol Ther, 2020, 20(2):125-140.
|
| 43 |
Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial[J]. Lancet Respir Med, 2019, 7(2):154-162.
|
| 44 |
Chan MCW, Kuok DIT, Leung CYH, et al. Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo[J]. Proc Natl Acad Sci U S A, 2016, 113(13):3621-3626.
|
| 45 |
Darwish I, Banner D, Mubareka S, et al. Mesenchymal stromal (stem) cell therapy fails to improve outcomes in experimental severe influenza[J]. PLoS One, 2013, 8(8):e71761.
|
| 46 |
Gotts J E, Abbott J, Matthay M A. Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal stem cell therapy[J]. Am J Physiol Lung Cell Mol Physiol, 2014, 307(5):L395-L406.
|
| 47 |
Chen J, Hu C, Chen L, et al. Clinical study of msc treating respiratory disttress syndrome induced by epidemic influenza a (H7N9)infection, a hint for covid-19 treatment[J]. Engineering (Beijing), 2020.DOI: 10.1016/j.eng.2020.02.006. Online ahead of print. |
| 48 |
Ntolios P, Manoloudi E, Tzouvelekis A, et al. Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose-derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis[J]. Clin Respir J, 2018, 12(6):2084-2089.
|
| 49 |
Chambers DC, Enever D, Ilic N, et al. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis[J]. Respirology, 2014, 19(7):1013-1018.
|
| 50 |
Stolk J, Broekman W, Mauad T, et al. A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema[J]. QJM, 2016, 109(5):331-336.
|
| 51 |
Armitage J, Tan DBA, Troedson R, et al. Mesenchymal stromal cell infusion modulates systemic immunological responses in stable COPD patients: a phase I pilot study[J]. Eur Respir J, 2018, 51(3):1702369.
|
| 52 |
Liang B, Chen J, Li T, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells[J]. ChinaXiv, 2020. DOI: 10.12074/202002.00084. |
| 53 |
Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 Pneumonia[J]. Aging Dis, 2020, 11(2):216-228.
|
| 54 |
Millar JE, von Bahr V, Malfertheiner MV, et al. Administration of mesenchymal stem cells during ECMO results in a rapid decline in oxygenator performance[J]. Thorax, 2019, 74(2):194-196.
|
| 55 |
Walczak P, Zhang J, Gilad AA, et al. Dual-Modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia[J]. Stroke, 2008, 39(5):1569-1574.
|
| 56 |
Loy H, Kuok DIT, Hui KPY, et al. Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza A(H5N1) Virus-associated acute lung injury[J]. J Infect Dis, 2019, 219(2):186-196.
|
| 57 |
Abreu SC, Weiss DJ, Rocco PR. Extracellular vesicles derived from mesenchymal stromal cells: a therapeutic option in respiratory diseases?[J]. Stem Cell Res Ther, 2016, 7(1):53.
|